Assessing the new and emerging treatments for atopic dermatitis

Lawrence F. Eichenfield, Sheila F. Friedlander, Eric L. Simpson, Alan D. Irvine

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


The newer and emerging treatments for atopic dermatitis (AD) focus on blockade of inflammatory cytokines, especially those that derive from T helper cell type 2 (TH2) and are associated with a pathway of immunoglobulin E (IgE) sensitization. Among the proinflammatory cytokines that have been identified as promising therapeutic targets are chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2), IgE, thymic stromal lymphopoietin (TSLP), and several monoclonal antibodies that block key cytokine pathways in the innate immune response. Two agents that have been studied in phase III clinical trials are the boronbased phosphodiesterase-4 (PDE-4) inhibitor, crisaborole, and dupilumab, an antibody that inhibits the interleukin-4/IL-13 receptor α chain.

Original languageEnglish (US)
Pages (from-to)92S-96S
JournalSeminars in cutaneous medicine and surgery
StatePublished - Jun 1 2016


  • Atopic dermatitis
  • Crisaborole
  • Dupilumab
  • Interleukin inhibitors
  • Petrolatum
  • Skin barrier

ASJC Scopus subject areas

  • Surgery
  • Dermatology


Dive into the research topics of 'Assessing the new and emerging treatments for atopic dermatitis'. Together they form a unique fingerprint.

Cite this